Equality Impact Assessment (Guidance development) (PDF 171 KB)
History
A list of downloadable documents created during development.
Expected publication
Final appraisal determination
Hepatitis C (chronic) - ombitasvir/paritaprevir/ritonavir (with or without dasabuvir): appraisal consultation
-
Hepatitis C (chronic) - ombitasvir/paritaprevir/ritonavir (with or without dasabuvir): appraisal consultation
-
Hepatitis C (chronic) - ombitasvir/paritaprevir/ritonavir (with or without dasabuvir): appraisal consultation document
-
-
-
-
-
Hepatitis C (chronic) - ombitasvir/paritaprevir/ritonavir (with or without dasabuvir): response to consultee and commentator comments on the draft scope and provisional matrix
-
Hepatitis C (chronic) - ombitasvir/paritaprevir/ritonavir (with or without dasabuvir): response to consultee and commentator comments on the draft scope and provisional matrix
-
Hepatitis C (chronic) - ombitasvir/paritaprevir/ritonavir (with or without dasabuvir): final matrix
-
Hepatitis C (chronic) - ombitasvir/paritaprevir/ritonavir (with or without dasabuvir): final matrix
-
Hepatitis C (chronic) - ombitasvir/paritaprevir/ritonavir (with or without dasabuvir): final scope
-
Hepatitis C (chronic) - ombitasvir/paritaprevir/ritonavir (with or without dasabuvir): final scope
-